Literature DB >> 7915507

Expression of proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NORs) in multiple myeloma.

A Skopelitou1, S Tselenis, S Theocharis, N Agnantis, A Tsenga, J Elemenoglou, M Hadjiyannakis, C Kittas.   

Abstract

We have studied 72 cases of multiple myeloma (MM) bone marrow trephine biopsies using the monoclonal antibody PC-10 and the colloid silver nitrate method for identification of proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NORs), respectively. PC-10 and AgNOR scores were statistically significantly different between low versus intermediate and low versus high grade of malignancy (P < 0.001), whereas their difference was not significant between intermediate and high grade. A strong correlation was identified between these two proliferation-associated indices in each histological grade. There is evidence that the proliferative state of myelomas belonging to the intermediate grade is approximately the same as that observed in high grade (blastic) ones.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915507

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Evaluation of argyrophilic nucleolar organiser regions (AgNORs) in multiple myeloma.

Authors:  S I Papadhimitriou; D Daskalopoulou; P Tsaftaridis; S Markidou; M Stamatelou
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  Biclonal primary plasma cell leukemia.

Authors:  Z Tóth; J Sipos
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.

Authors:  G Tsirakis; C A Pappa; M Kaparou; V Katsomitrou; A Hatzivasili; T Alegakis; A Xekalou; E N Stathopoulos; M G Alexandrakis
Journal:  Eur J Histochem       Date:  2011-08-27       Impact factor: 3.188

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.